Early breast cancer Trialists' collaborative group. Polychemotherapy for early breast cancer:an overview of the randomised trials[J]. Lancet,1998,352(9132):930-942.
[3]
Roché H. Evolving strategies over time for treatment of breast cancer[J]. Bull Cancer,2013,100(9):857-863.
[4]
Kaufmann M,Jonat W,Abel U,et al. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer[J]. J Clin Oncol,1993,11(3):454-460.
[5]
White IN. Tamoxifen:is it safe Comparison of activation and detoxication mechanisms in rodents and in humans[J]. Curr Drug Metab,2003,4(3):223-239.
[6]
Jordan VC. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer[J]. Steroids,2007,72(13):829.
[7]
Goetz MP,Kamal A,Ames MM. Tamoxifen pharmacogenomics:The role of CYP2D6 as a predictor of drug response[J]. Clin Pharmaco Ther,2008,83(1):160.
[8]
Lim HS,Ju LH,Seok IX,et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen phannaeokinetics in metastatic breast cancer[J]. J Clin Oneol,2007,25(25):3837.
[9]
Kiyotani K,Mushiroda T,Sasa M,et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy[J]. Cancer Sci,2008,99(5):995.
